IN2014DN10075A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10075A
IN2014DN10075A IN10075DEN2014A IN2014DN10075A IN 2014DN10075 A IN2014DN10075 A IN 2014DN10075A IN 10075DEN2014 A IN10075DEN2014 A IN 10075DEN2014A IN 2014DN10075 A IN2014DN10075 A IN 2014DN10075A
Authority
IN
India
Prior art keywords
medicine
allodynia
preventing
caused
active ingredient
Prior art date
Application number
Other languages
English (en)
Inventor
Atsufumi Kawabata
Hideaki Suzuki
Original Assignee
Univ Kinki
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kinki, Asahi Kasei Pharma Corp filed Critical Univ Kinki
Publication of IN2014DN10075A publication Critical patent/IN2014DN10075A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/366Thrombomodulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/7455Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10075DEN2014 2012-05-31 2013-05-17 IN2014DN10075A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤

Publications (1)

Publication Number Publication Date
IN2014DN10075A true IN2014DN10075A (cs) 2015-08-21

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10075DEN2014 IN2014DN10075A (cs) 2012-05-31 2013-05-17

Country Status (20)

Country Link
US (1) US10709767B2 (cs)
EP (1) EP2857037B1 (cs)
JP (3) JP6124417B2 (cs)
KR (1) KR101672114B1 (cs)
CN (1) CN104394885B (cs)
AU (1) AU2013268725B2 (cs)
BR (1) BR112014028852A2 (cs)
CA (1) CA2875069C (cs)
DK (1) DK2857037T3 (cs)
ES (1) ES2743767T3 (cs)
HU (1) HUE045997T2 (cs)
IL (1) IL235984B (cs)
IN (1) IN2014DN10075A (cs)
MX (1) MX364934B (cs)
NZ (1) NZ702242A (cs)
PL (1) PL2857037T3 (cs)
PT (1) PT2857037T (cs)
RU (1) RU2595857C2 (cs)
WO (1) WO2013179910A1 (cs)
ZA (1) ZA201408769B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10075A (cs) * 2012-05-31 2015-08-21 Univ Kinki
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
SG11201909104PA (en) * 2017-03-31 2019-11-28 Toray Industries Therapeutic or prophylactic agent for peripheral neuropathies
EP3727367A4 (en) * 2017-12-19 2021-10-27 Synergia Life Sciences Pvt. Ltd COMPOSITIONS OF VITAMIN K2 FOR THE TREATMENT OF DRUG-INDUCED NEUROPATHY
US11497795B2 (en) * 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
AU2019347406B9 (en) * 2018-09-28 2023-11-16 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインcの活性化を促進する作用を有するペプチド
DE3856335T2 (de) 1987-01-08 2000-01-27 Asahi Kasei Kogyo K.K., Osaka Peptid zur beschleunigung der wirkung des proteins-c mit thrombin
EP0285511B1 (en) 1987-04-01 1992-11-25 Mitsubishi Gas Chemical Company, Inc. Immunoassay of thrombomodulin
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
WO1992000325A1 (en) 1990-06-27 1992-01-09 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
DE69434942T2 (de) 1993-02-25 2007-11-29 Abbott Laboratories, Abbott Park Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
DE69534016T2 (de) 1994-04-20 2006-03-23 Asahi Kasei Pharma Corp. Verwendung von thrombomodulin gegen lebererkrankungen
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインcの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
DE69634773T2 (de) 1995-03-06 2006-05-04 Interneuron Pharmaceuticals, Inc., Lexington Verminderung des infarktausmasses unter verwendung von citicolin
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
CA2404231A1 (en) 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
EP1664041B1 (en) * 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
WO2006089233A2 (en) * 2005-02-16 2006-08-24 Wyeth Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
JP5453258B2 (ja) 2007-07-13 2014-03-26 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム カンナビノイド受容体の複素環式モジュレーター
CA2712640A1 (en) * 2008-02-18 2009-08-27 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
US20110144024A1 (en) * 2008-07-16 2011-06-16 Paion Deutschland Gmbh Prevention and treatment of radiation injury
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および/または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び/又は治療のための医薬
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
IN2014DN10075A (cs) * 2012-05-31 2015-08-21 Univ Kinki

Also Published As

Publication number Publication date
JP2018095652A (ja) 2018-06-21
CN104394885A (zh) 2015-03-04
CA2875069A1 (en) 2013-12-05
US20150148296A1 (en) 2015-05-28
JP6427284B2 (ja) 2018-11-21
JP6279788B2 (ja) 2018-02-14
KR20150004855A (ko) 2015-01-13
CN104394885B (zh) 2017-06-30
EP2857037A4 (en) 2016-04-06
PT2857037T (pt) 2019-07-19
JP6124417B2 (ja) 2017-05-10
EP2857037A1 (en) 2015-04-08
WO2013179910A1 (ja) 2013-12-05
HUE045997T2 (hu) 2020-01-28
MX2014014505A (es) 2015-06-02
JP2017141268A (ja) 2017-08-17
ES2743767T3 (es) 2020-02-20
EP2857037B1 (en) 2019-06-26
HK1203846A1 (en) 2015-11-06
IL235984A0 (en) 2015-01-29
PL2857037T3 (pl) 2019-12-31
BR112014028852A2 (pt) 2018-04-24
AU2013268725B2 (en) 2017-02-16
KR101672114B1 (ko) 2016-11-02
ZA201408769B (en) 2015-12-23
JPWO2013179910A1 (ja) 2016-01-18
AU2013268725A1 (en) 2014-12-18
US10709767B2 (en) 2020-07-14
NZ702242A (en) 2016-03-31
DK2857037T3 (da) 2019-07-22
RU2595857C2 (ru) 2016-08-27
RU2014148171A (ru) 2016-07-20
CA2875069C (en) 2018-01-02
MX364934B (es) 2019-03-28
IL235984B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
ZA201708692B (en) Antibacterial compounds
PH12017501306A1 (en) Inhibitors of histone demethylases
WO2016142445A3 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
IN2014DN10075A (cs)
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
SG10201903119QA (en) Polypeptide vaccine
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12014501573A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3220920A4 (en) Combination therapy effective against microorganisms, including drug resistant microorganisms
WO2015027121A3 (en) Cancer treatment
IL234874B (en) Triazinone compound having an inhibitory activity on a t-type calcium channel, preventive agents, therapeutic agents and medicines containing it as an active component
WO2014053962A3 (en) Compositions and methods for treatment of diabetes and pre-diabetes
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
UA89548U (ru) Фармацевтическая аэрозольная композиция для лечения бактериальных вагинозов
MX2017011093A (es) Terapia combinada de roneparstat para mieloma multiple.
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز